Download PDF
Thromb Haemost 2001; 85(05): 932-934
DOI: 10.1055/s-0037-1615771
Letters to the Editor
Schattauer GmbH

Rebuttal to: Oral Contraceptives and Venous Thromboembolism

M. Greaves
1   Department of Medicine and Therapeutics, University of Aberdeen, and Department of Haematology, University of Sheffield, UK
,
F. E. Preston
1   Department of Medicine and Therapeutics, University of Aberdeen, and Department of Haematology, University of Sheffield, UK
› Author Affiliations
Further Information

Publication History

Received 16 November 2001

Accepted 22 December 2000

Publication Date:
11 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Kluft C. Renewed interest in haemostasis changes induced by oral contraceptives. Thromb Haemost 2000; 84: 1-3.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.. Effects of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8.
    CrossrefPubMedGoogle Scholar
  • 3 Parkin L, Skegg DCG, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet 2000; 355: 2133-4.
    CrossrefPubMedGoogle Scholar
  • 4 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third generation oestrogens. Lancet 1995; 346: 1593-6.
    CrossrefPubMedGoogle Scholar
  • 5 Jick H, Jick SS, Gurewich V, Myers MW, Vasilikis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
    CrossrefPubMedGoogle Scholar
  • 6 Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and Health of Young Women. Brit Med J 1996; 312: 83-8.
    CrossrefPubMedGoogle Scholar
  • 7 Herings RMC, Urquhart J, Leufkens HGM. Venous thromboembolism among new users of different oral contraceptives. Lancet 1999; 354: 127-8.
    CrossrefPubMedGoogle Scholar
  • 8 Mellemkjaer L, Sorensen HT, Dreyer L, Olsen J, Olsen JH. Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark 1977-95. Brit Med J 1999; 319: 820-1.
    CrossrefPubMedGoogle Scholar
  • 9 Rosing J, Tans G, Nicolaes GAF, Thomassen MCGLD, van Oerle R, van der Ploeg PMEN, Heijnen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Brit J Haematol 1997; 97: 233-8.
    CrossrefPubMedGoogle Scholar
  • 10 Rosing J, Middeldorp S, Curvers J, Thomassen MCCGD, Nicolaes GAF, Meijers JCM, Bouma BN, Büller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 354: 2036-40.
    CrossrefPubMedGoogle Scholar
  • 11 Tans G, Rosendaal FR, Curvers J, Thomassen MCLGD, Bertina RM, Vandenbroucke JP. APC resistance determined with the endogenous thrombin potential is associated with venous thrombosis: a blinded clinical evaluation. Thromb Haemost 1999; 640: 202-3.
    PubMedGoogle Scholar
  • 12 Middeldorp S, Meijers JCM, van den Ende AE, van Enk A, Bouma BM, Tans G, Rosing J, Prins MH, Buller HR. Effects on coagulation of Levonorgestrel- and Desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 84: 4-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Meijers JCM, Middeldorp S, Tekelenberg W, van den Ende AE, Tans G, Prins MH, Rosing J, Buller HR, Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis. A randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 2000; 84: 9-14.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Tans G, Curvers J, Middeldorp S, Thomassen MCLGD, Meijers JCM, Prins MH, Bouma BM, Buller HR, Rosing J. A randomized cross-over study on the efects of Levonorgestrel- and Desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Heinemann LAJ, Assman A, Spannag M, Schramm W, Dick A, Kluft C, de Maat MPM. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception 1998; 58: 321-2.
    CrossrefPubMedGoogle Scholar
  • 16 Skegg DCG. Third generation oral contraceptives. Caution is still justified. Brit Med J 2000; 321: 190-1.
    CrossrefPubMedGoogle Scholar
  • 17 Farley TMM, Meirik M, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum Reprod Update 1999; 5: 721-35.
    CrossrefPubMedGoogle Scholar
  • 18 Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risks of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 83-8.
    CrossrefPubMedGoogle Scholar
  • 19 Farmer RDT, Williams TJ, Simpson EL, Nightingale AL. Effect of 1995 pill scare on rates of venous thromboembolism among women taking combined oral contraceptives: analysis of General Practice Research Database. Brit Med J 2000; 321: 477-9.
    CrossrefPubMedGoogle Scholar
  • 20 Walker AM. Backsliding into correlations. BMJ. http://www.bmj.com/cgieletters/321/7529/477
    PubMedGoogle Scholar
  • 21 Vandenbroucke JP, Helmerhorst FM, Rosendaal FR. Competing interests and controversy about third generation oral contraceptives. Brit Med J 2000; 320: 381-2.
    CrossrefPubMedGoogle Scholar